Skip to main content

Research Repository

Advanced Search

Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients

Anderson, Elizabeth; Salisbury, Vyv

Authors

Vyv Salisbury



Contributors

T Scheper
Editor

A Belkin
Editor

PM Doran
Editor

I Endo
Editor

MB Gu
Editor

WS Hu
Editor

B Mattiasson
Editor

J Nielsen
Editor

GN Stephanopoulos
Editor

R Ulber
Editor

A-P Zeng
Editor

J-J Zhong
Editor

W Zhou
Editor

S Harald
Editor

Abstract

© Springer-Verlag Berlin Heidelberg 2014. Bioluminescent bacterial biosensors can be used in a rapid in vitro assay to predict sensitivity to commonly used chemotherapy drugs in acute myeloid leukemia (AML). The nucleoside analog cytarabine (ara-C) is the key agent for treating AML; however, up to 30% of patients fail to respond to treatment. Screening of patient blood samples to determine drug response before commencement of treatment is needed. To achieve this aim, a self-bioluminescent reporter strain of Escherichia coli has been constructed and evaluated for use as an ara-C biosensor and an in vitro assay has been designed to predict ara-C response in clinical samples. Transposition mutagenesis was used to create a cytidine deaminase (cdd)-deficient mutant of E. coli MG1655 that responded to ara-C. The strain was transformed with the luxCDABE operon and used as a whole-cell biosensor for development an 8-h assay to determine ara-C uptake and phosphorylation by leukemic cells. Intracellular concentrations of 0.025 lmol/L phosphorylated ara-C were detected by significantly increased light output (P\0.05) from the bacterial biosensor. Results using AML cell lines with known response to ara-C showed close correlation between the 8-h assay and a 3-day cytotoxicity test for ara-C cell killing. In retrospective tests with 24 clinical samples of bone marrow or peripheral blood, the biosensor-based assay predicted leukemic cell response to ara-C within 8 h. The biosensor-based assay may offer a predictor for evaluating the sensitivity of leukemic cells to ara-C before patients undergo chemotherapy and allow customized treatment of drug-sensitive patients with reduced ara-C dose levels. The 8-h assay monitors intracellular ara-CTP (cytosine arabinoside triphosphate) levels and, if fully validated, may be suitable for use in clinical settings.

Journal Article Type Article
Publication Date Jan 1, 2014
Journal Advances in Biochemical Engineering/Biotechnology
Print ISSN 0724-6145
Publisher Springer Verlag
Peer Reviewed Not Peer Reviewed
Volume 145
Pages 189-214
Series Title Advances in Biochemical Engineering/Biotechnology
Book Title Bioluminescence: Fundamentals and Applications in Biotechnology - Volume 2
ISBN 0724-6145
DOI https://doi.org/10.1007/978-3-662-43619-6_6
Keywords in-vitro testing, chemotherapy, leukaemia
Public URL https://uwe-repository.worktribe.com/output/822778
Publisher URL http://dx.doi.org/10.1007/978-3-662-43619-6_6
Related Public URLs http://link.springer.com/book/10.1007/978-3-662-43619-6